The GvHD Hub was pleased to speak with Corey Cutler, Dana-Farber Cancer Institute, Boston, US. We asked, What are the treatment options for chronic GvHD-associated fibrosis?

In this interview, Cutler discusses the development and clinical impact of fibrotic manifestations in chronic graft-versus-host disease (cGvHD), and explores the U.S. Food and Drug Administration (FDA)-approved therapies, including ibrutinib, ruxolitinib, belumosudil, and axatalimab, and the differences in their mechanisms of actions that may influence their use in the treatment of fibrotic disease. He also considers how novel antifibrotic agents might be integrated into the management of fibrotic cGvHD in the future.

This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

During the GvHD Hub Steering Committee Meeting in December 2025, key opinion leaders met to discuss the mechanism of action and clinical data supporting the use of mesenchymal stromal cells (MSCs) for the treatment of graft-versus-host disease (GvHD). The meeting opened with a presentation by Robert Zeiser and featured a discussion including Mohamad Mohty, Yi-Bin Chen, Daniel Wolff, Florent Malard, Corey Cutler, and Andrew Harris.

During his presentation, Zeiser outlined the proposed mechanism of action of MSCs, describing how they promote an immunosuppressive and immunoregulatory environment. He explored the evolving clinical trial landscape of MSCs in the treatment of GvHD, beginning with the first reported use in 2004, and summarized key trial results leading to the approval of the MSC products remestemcel-L and JR-031. Zeiser highlighted the challenge of MSC product variability, which has contributed to heterogenous response rates across studies. He introduced MSC-Frankfurt am Main (FFM), an MSC product generated by pooling bone marrow-derived mononuclear cells from eight human leukocyte antigen (HLA)-disparate donors to reduce variability. He also explored MSC-FFM outcomes across real-world cohorts and presented the study designs of two ongoing phase II/III trials.

This discussion topic is supported by Medac, who provided funding. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion.

Hosted on Acast. See acast.com/privacy for more information.

The GvHD Hub held a virtual symposium on October 21, 2025, titled, Guidance vs practice: How can we improve treatment of SR-GvHD? Here, we share a presentation by Daniel Wolff, University Hospital Regensburg, DE, discussing the early treatment strategies for SR-GvHD.

Wolff provided an overview of the treatment options for second-line treatment after steroids and subsequent advanced-line options, emphasizing that early detection of disease progression and sufficient treatment intervention are crucial, as advanced disease is often nonreversible. Wolff discussed response assessments to first-line steroid treatment and second-line treatments, and outlined the treatment options for patients with SR-cGvHD, including ruxolitinib, belumosudil, axatilimab, ibrutinib, and extracorporeal photopheresis.

This educational resource is independently supported by Sanofi.​

All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.